Hormone Therapy Linked to Greater Semaglutide Weight Loss
A study presented at The Menopause Society meeting found midlife women using hormone therapy lost more weight on semaglutide than nonusers.
Updated on Nov. 9, 2026 in Weight Loss
Live Poll
Do you think hormone therapy helps midlife women lose more weight?
Researchers presented findings at The Menopause Society annual meeting in San Diego from October 20 to 24, reporting that midlife women using hormone therapy lost more weight on semaglutide than those not using it. Among 2,379 women in the semaglutide cohort, hormone therapy users lost 9.8 percent of total body weight at nine months versus 8.2 percent for nonusers.
Why it matters
The results suggest hormone therapy status may influence how midlife women respond to widely prescribed weight-loss medications. The findings add to questions about whether menopause-related factors should be considered when evaluating treatment outcomes.
The analysis compared 793 semaglutide hormone therapy users with 1,586 nonusers and 492 tirzepatide hormone therapy users with 984 nonusers, using propensity score matching. Differences in the tirzepatide group were not significant at later timepoints or for higher weight-loss thresholds.
The players
The Menopause Society
The Menopause Society is a professional medical organization focused on midlife women's health and menopause care, which hosted the annual meeting where the study was presented.
Mayo Clinic Florida
Mayo Clinic Florida is the Jacksonville campus of the Mayo Clinic, a major academic medical center whose researchers were involved in the study.
The details
Women aged 45 or older with a body mass index of 27 kg/m2 or higher were included in the analysis. Women using hormone therapy were more likely to achieve at least 10, 20, 25, and 30 percent total body weight loss on semaglutide.
Timeline
October 20 to 24, 2026: Study presented at the annual Menopause Society meeting in San Diego.
Nine months: Semaglutide hormone therapy group begins showing significantly greater weight loss.
Three months: Tirzepatide hormone therapy group shows modestly greater weight loss.
Health Landscape
The findings were presented at The Menopause Society annual meeting, a venue where clinicians review evidence on hormone therapy in midlife women. The study adds to a growing body of research examining how semaglutide and tirzepatide perform across different patient populations.
Women using hormone therapy may want to discuss with their clinicians whether menopause treatment could affect their response to semaglutide or tirzepatide. The study does not establish a recommendation to change current prescribing.
The takeaway
Hormone therapy status may be one factor clinicians consider when assessing weight-loss medication outcomes in midlife women. Patients should review treatment expectations with their healthcare providers.
Further reading
For related coverage, explore our Weight Loss section.
Source note: This article includes information reported by Renal and Urology News.
Live Poll
Do you think hormone therapy helps midlife women lose more weight?
